Schwarz Neupro Phase III PD data

Schwarz (Monheim, Germany) said that in a U.S. Phase III trial in 351 patients with advanced stage idiopathic Parkinson's disease (PD), Neupro rotigotine transdermal patch met the co-primary endpoints of an absolute change in off-time compared to baseline and an increase in the number of patients who experienced a 30% reduction in off-time compared to baseline. ...